论文部分内容阅读
目的:探究美托洛尔联合稳心颗粒治疗冠心病合并室性期前收缩的临床疗效;方法:选取2015年1月至2016年10月东莞市人民医院收治的120例冠心病合并室性期前收缩患者,根据治疗方案差异,分为对照组1、对照组2和观察组,各40例,对照组1给予口服药物美托洛尔,对照组2给予稳心颗粒,观察组同时给予美托洛尔和稳心颗粒,比较3组的临床治疗效果和不良反应发生率。结果:对照组1、对照组2和观察组的治疗总有效率分别为77.5%、72.5%和95.0%,两组对照组间比较,差异无统计学意义(P>0.05),观察组与两组对照组相比,差异具有统计学意义(P<0.05);对照组1、对照组2和观察组的不良反应发生率分别为7.5%、5.0%和2.5%,两组对照组间比较,差异无统计学意义(P>0.05),观察组不良反应发生率明显低于对照组1和对照组2,差异具有统计学意义(P<0.05)。结论:采用美托洛尔与稳心颗粒联合治疗冠心病合并室性期前收缩的治疗方案具有良好的临床效果,可有效降低美托洛尔引起的不良反应。
Objective: To investigate the clinical efficacy of metoprolol combined with Wenxin Granule in the treatment of coronary heart disease complicated with ventricular premature contraction. Methods: From January 2015 to October 2016, 120 patients with coronary heart disease Patients with pre-contractions were divided into control group (1), control group (2) and observation group (40 cases), while control group (1) received metoprolol as oral drug and control group (2) Tolrolol and Wenxin Granules, the clinical efficacy of the three groups compared with the incidence of adverse reactions. Results: The total effective rates of control group 1, control group 2 and observation group were 77.5%, 72.5% and 95.0%, respectively. There was no significant difference between the two control groups (P> 0.05) The difference was statistically significant (P <0.05). The incidence of adverse reactions in control group 1, control group 2 and observation group were 7.5%, 5.0% and 2.5% respectively. There were significant differences between the two control groups The difference was not statistically significant (P> 0.05). The incidence of adverse reactions in observation group was significantly lower than that in control group 1 and control group 2 (P <0.05). Conclusion: The combination of metoprolol and Wenxin Granule in the treatment of coronary heart disease complicated with premature ventricular contraction has a good clinical effect, which can effectively reduce the adverse reactions caused by metoprolol.